



Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. ("Poseida"), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that preclinical data on P-PSMA-101, the company's PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held November 8-12, 2017 in National Harbor, Maryland.

"P-PSMA-101 is a CAR-T cell therapeutic that exhibits a persistently high percentage of stem cell memory T-cells and mediates durable anti-solid tumor efficacy that surpasses previously established anti-PSMA CAR T-cell therapy in several *in vivo* models," said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida. "Future efforts will continue towards clinical application of P-PSMA-101 in patients with metastatic castrate resistance prostate cancer."

The following study will be presented:

Presentation Title: PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model

Presenter: Jenessa Smith, Ph.D., Poseida Therapeutics

Date and Time: 12:30-2:00 p.m. and 6:30-8:00 p.m., Saturday, November 11, 2017

Abstracts are available online at the [SITC conference website](#). Following the presentation on November 11, a poster presentation will be available on the publications page of Poseida's website at www.poseida.com/publications.

About P-PSMA-101

P-PSMA-101 is a CAR-T immunotherapy designed to supercharge a patient's own T cells to safely and effectively eliminate tumor cells carrying prostate-specific membrane antigen (PSMA), which is expressed on the majority of prostate cancer cells. P-PSMA-101 employs a PSMA-specific Centyrin™ binding domain and is engineered using a non-viral gene delivery system called the piggyBac™ DNA Modification System, which leverages the technology's capability to deliver 30 times more cargo than traditional virus-based CAR T-cell modification systems. P-PSMA-101 has demonstrated potent anti-tumor activity, persistent and durable response, significant T-cell memory, a high concentration of P-PSMA-101 modified T-cells and no T-cell exhaustion. A unique feature of P-PSMA-101 and other Poseida CAR-T products is their exceptionally high percentage of stem cell memory T cells, which has been shown in preclinical studies to lead to unprecedented durability of response without re-administration of treatment.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is translating best-in-class gene therapy technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for cancer, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene therapy technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Edit (FFGE). For more information, visit www.poseida.com.

Corporate Communications Contact:

Jason Spark

Canale Communications

619-849-6005

Jason@canalecomm.com